KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Inovio Pharmaceuticals (INO) over the last 15 years, with Q3 2025 value amounting to $22.5 million.

  • Inovio Pharmaceuticals' Gains from Investment Securities changed N/A to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 126542.57%. This contributed to the annual value of -$2.8 million for FY2024, which is 4155.8% up from last year.
  • Inovio Pharmaceuticals' Gains from Investment Securities amounted to $22.5 million in Q3 2025.
  • Inovio Pharmaceuticals' 5-year Gains from Investment Securities high stood at $22.5 million for Q3 2025, and its period low was -$5.4 million during Q4 2022.
  • Its 5-year average for Gains from Investment Securities is $565817.0, with a median of -$148.0 in 2023.
  • In the last 5 years, Inovio Pharmaceuticals' Gains from Investment Securities surged by 30236.39% in 2022 and then plummeted by 54151.73% in 2023.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Gains from Investment Securities stood at -$4.6 million in 2021, then fell by 17.56% to -$5.4 million in 2022, then skyrocketed by 82.46% to -$952113.0 in 2023, then plummeted by 60.66% to -$1.5 million in 2024, then surged by 1571.95% to $22.5 million in 2025.
  • Its last three reported values are $22.5 million in Q3 2025, $1.9 million for Q2 2025, and -$3.7 million during Q1 2025.